IDD 3
Alternative Names: IDD-3; Melanoma vaccine - IDM Pharma; UvidemLatest Information Update: 02 Oct 2021
At a glance
- Originator IDM Pharma
- Developer Takeda America Holdings
- Class Antineoplastics; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
- 25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
- 06 Nov 2007 Updated results from a phase II clinical trial (DC-MEL-202) in patients with advanced melanoma added to the Cancer therapeutic trials section